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ABSTRACT 
Background: Dairy products may be involved in the etiology of inflammatory bowel disease by 
modulating gut microbiota and immune responses, but data from epidemiological studies 
examining this relationship are limited. We investigated the association between prediagnostic 
intake of these foods and dietary calcium and the subsequent development of Crohn’s disease 
(CD) and ulcerative colitis (UC). 
Methods: In total, 401,326 participants were enrolled in the European Prospective Investigation 
into Cancer and Nutrition cohort. At recruitment, consumption of total and specific dairy 
products (milk, yogurt, cheese) and dietary calcium was measured using validated food 
frequency questionnaires. Cases developing incident CD (n=110) or UC (n=244) during follow-
up were matched with four controls. Conditional logistic regression analyses were used to 
calculate odds ratios (ORs) with 95% confidence intervals (CIs), adjusted for total energy intake 
and smoking. 
Results: Compared with the lowest quartile, the ORs for the highest quartile of total dairy 
products and dietary calcium intake were 0.61 (95% CI 0.32-1.19, p trend=0.19) and 0.63 (95% CI 
0.28-1.42, p trend=0.23) for CD and 0.80 (95% CI 0.50-1.30, p trend=0.40) and 0.81 (95% CI 0.49-
1.34, p trend=0.60) for UC. Compared with nonconsumers, individuals consuming milk had 
significantly reduced odds of CD (OR 0.30, 95% CI 0.13-0.65) and nonsignificantly reduced odds 
of UC (OR 0.85, 95% CI 0.49-1.47).  
Conclusions: Milk consumption may be associated with a decreased risk of developing CD, 
although a clear dose-response relationship was not established. Further studies are warranted 
to confirm this possible protective effect. 
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Introduction 
Inflammatory bowel disease (IBD) is characterized by recurrent inflammation of the 
gastrointestinal tract and comprises two main conditions: Crohn’s disease (CD) and ulcerative 
colitis (UC). Both chronic disorders are considered to result from an impaired immune response 
to gut microbiota in genetically predisposed individuals, but the exact etiology remains 
unclear.1,2 Although over 160 susceptibility loci for IBD have been identified,3 the limited 
concordance rates in identical twins highlight the importance of environmental risk factors.4-6 
The changing epidemiology of IBD, with both a rise in the incidence in industrialized countries 
over the last century and the recent disease emergence in developing countries,7,8 suggests that 
westernization of lifestyle, including dietary changes, may contribute to the etiology of CD and 
UC.9,10  
Dairy products are common components of a western diet and are being increasingly consumed 
in developing nations.11 These milk-based foods constitute an important source of fats, proteins 
and dietary calcium,12 and could be implicated in the development of IBD by modulating effects 
on intestinal microbiota and immune responses. Both molecular and clinical studies suggest that 
dairy nutrients are inversely associated with low-grade inflammation and affect key cytokines in 
the pathogenesis of IBD, such as tumor necrosis factor alpha.13,14 However, milk-derived 
saturated fats may promote a rise in inflammatory markers by influencing cytokine gene 
expression.13 Alternatively, consumption of (fermented) milk products may have a significant 
impact on the composition of gut microbes, such as lactic acid bacteria, which may result in 
disparate effects on intestinal inflammation.15-18  
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Despite plausible biological mechanisms linking dairy products to the etiology of IBD, there are 
few epidemiological studies which have examined the relationship between these foods and the 
development of either CD or UC.19 An ecological study has reported a strong positive 
association between the intake of milk proteins and the incidence of CD in Japan.20 However, 
several retrospective case-control studies have documented either no or small inverse 
associations between dairy products and IBD, but may have been subject to selection bias and 
recall bias in the assessment of presymptomatic diet.21-24 A single prospective study in a French 
cohort of women has reported no association, although the sample size was relatively small and 
the risks for CD and UC were not separately assessed.25 In view of the inconsistent findings of 
previous investigations and the lack of large prospective studies, we aimed to explore the 
association between the intake of total and individual dairy products and dietary calcium and 
incident CD and UC in the European Prospective Investigation into Cancer and Nutrition (EPIC) 
cohort.  
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Materials and Methods 
Study population  
The EPIC cohort study was designed to investigate the relationship between diet and the 
incidence of cancer and chronic diseases, the methods of which have been previously 
described.26 In this study, participants were from a subcohort (EPIC-IBD study), namely 401,326 
initially healthy men and women (aged 20-80 years) recruited from twelve centers in Denmark, 
France, Germany, Greece, Italy, the Netherlands, the United Kingdom (UK) and Sweden between 
1991 and 1998.27 Participants were selected from the general population in all centers, apart 
from France (women in a health insurance scheme for teachers), Utrecht, the Netherlands 
(women in a breast cancer screening program) and Oxford, UK (nationwide members of 
vegetarian societies and readers of health food magazines). At baseline, information on age, 
gender, diet, smoking and physical activity was collected in self-administered questionnaires. 
Anthropometric measurements were mainly taken by qualified health professionals or in few 
centers obtained through participants’ self-reports.  
 
Dietary assessment 
The habitual diet of participants, during the year before recruitment, was assessed by self-
completion of validated country-specific food frequency questionnaires (FFQs), composed of 
approximately 200 food items and nine frequency categories of intake (never to several times 
per day). The FFQs were validated against a standard 24-hour recall questionnaire in all centers 
and a Spearman correlation coefficient of 0.68 was documented for the intake of dairy 
products.28 National databases of food composition were used to calculate the daily intakes of 
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specific dairy foods (in grams) and total energy (in kilocalories). Subjects with a reported total 
energy intake in either the lowest or highest 1% values across the distribution of the whole 
cohort were excluded, as these values were considered implausible.  
Individual dairy products consisted of milk, yogurt and cheese. Milk included all the subtypes 
(whole fat, skimmed, semi-skimmed and unspecified). Yogurt comprised natural and flavored 
products, and fermented milk in Denmark and Sweden. Cheese was either fresh, fermented or 
matured cheese products. Other types of dairy products, including milk containing beverages, 
curd, cream desserts and milk-based puddings, dairy creams and milk for coffee and creamers, 
were not analyzed individually, as for these there were relatively low intakes and incomplete 
measurements across centers. The total dairy products intake was recorded as the sum of all 
types of dairy products. The standardized EPIC Nutrient Database was used to calculate the daily 
consumption of dietary calcium (in milligrams), which did not consider the use of calcium 
supplements.29  
 
Follow-up & identification of cases and controls 
After recruitment, participants were followed up until at least June 2004 and in some centers 
until December 2010. Individuals who developed a new diagnosis of CD or UC were identified 
using population-based disease registries (Denmark, Italy, the Netherlands and Sweden) or 
follow-up questionnaires (France, Germany, Greece and the Oxford cohort (UK)). Incident IBD 
cases within the Norfolk cohort (UK) were identified by several methods, including follow-up 
questionnaires, inpatient records and histology databases. The medical notes of all potential 
cases were reviewed by local physicians to confirm the diagnoses and to provide information on 
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the diagnostic examinations and disease extent. Individuals with prevalent CD or UC at 
enrolment were excluded, as were those diagnosed with IBD less than 18 months after 
recruitment to minimize the risk of reverse causation. In this case-control study nested within a 
prospective cohort, each case was matched with four randomly selected unique controls for 
gender, age at recruitment (±6 months), date of recruitment (±3 months) and center. Controls 
were selected by incidence density matching to ensure a similar duration of follow-up for all 
individuals. None of the controls had CD, UC, indeterminate or microscopic colitis. 
 
Statistical analysis 
The dietary items of interest were compared between cases and controls using the appropriate 
statistical test according to the nature of their distributions. The intakes of total and individual 
dairy products and dietary calcium were divided into quartiles based on the distribution across 
the matched controls. Conditional logistic regression analyses were performed to assess the 
associations between the intake of dairy products and dietary calcium and the development of 
CD and UC separately by calculating odds ratios (ORs) with 95% confidence intervals (CIs). In the 
multivariable analysis, total energy intake and smoking status (categorized into never smoked, 
past smoker and current smoker) were added to the model. Energy adjustment was included to 
adjust for factors affecting dietary intake, namely body size, metabolic rate and physical 
activity,30 whereas adjustment for smoking status was included because previous 
epidemiological studies consistently demonstrated associations between this factor and IBD.31 
Trends across quartiles were computed using the median value of each as a continuous variable. 
The analyses were repeated, including additional adjustment for socioeconomic status using 
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educational level (categorized into none, primary school, technical school, secondary school and 
higher education), as this factor has been associated with both IBD and the consumption of 
dairy products.32-35 Excluding adjustment for energy intake was performed to assess whether the 
effects of dairy products or dietary calcium intake might be due to substitution for consumption 
of other food items. When possible, the risk of CD or UC was evaluated for consumers as 
compared to nonconsumers of dairy products. Stratified analyses were performed to assess 
whether associations differed according to disease site (ileal or colonic CD, left sided or 
extensive UC).  In further analyses, cases diagnosed within 3 years or more than 5 years after 
enrolment respectively were excluded to further reduce the possibility of reverse causation and 
to evaluate if the intake of these dietary items may be related more closely to the development 
of IBD and time of diagnosis. Two-sided p-values below 0.05 were considered statistically 
significant. All analyses were performed using SPSS version 21 (IBM Corp., Armonk, New York, 
United States).  
 
Ethical considerations 
Ethical approval was obtained at each center and all participants gave written informed consent. 
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Results 
During follow-up, 110 participants (72.7% female) developed CD at a mean age of 55.4 years 
and 244 participants (57.4% female) developed UC at a mean age of 57.5 years (Table 1). The 
median time between recruitment and diagnosis was 5.1 years (range 1.5-14.3 years) and 4.8 
years (range 1.5-15.7 years) for CD and UC, respectively. Colonic disease was the commonest 
disease site in CD (32.7%), whereas left-sided colitis (involvement limited up to the splenic 
flexure) was the commonest phenotype in UC (35.2%). The completeness of the dietary data was 
100.0% for CD cases, 98.0% for UC cases and 99.5% for each matched control group. The 
median intakes of total and specific dairy products and dietary calcium were similar between CD 
or UC cases and their controls.  
There were no statistically significant associations according to quartiles or trends between the 
intake of total or individual dairy products or dietary calcium and the development of either CD 
or UC in the univariable analysis (Tables 2 and 3). In the multivariable analysis, adjusted for total 
energy intake and smoking status, the effect sizes were similar and no significant associations 
were observed. However, compared with nonconsumers, individuals consuming milk had 
significantly decreased odds of developing CD (OR 0.30, 95% CI 0.13-0.65) but did not have 
significantly reduced odds of developing UC (OR 0.85, 95% CI 0.49-1.47) (Table 4). Additional 
adjustment for educational level or excluding adjustment for total energy intake did not alter 
the magnitude of any effect sizes (data not shown). There was a significant inverse association 
according to quartiles between milk intake and colonic CD (p trend=0.07) in the multivariable 
analysis, whereas no associations according to disease localization were observed for UC or 
other dairy products for CD (Table 5). The analyses in cases diagnosed within 5 years of 
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recruitment (CD: n=53; UC: n=127) showed significant inverse associations according to 
quartiles between total dairy products and milk intake and CD (median time between 
recruitment and diagnosis 3.2 years), with adjusted ORs for the highest versus lowest quartile of 
0.36 (95% CI 0.15-0.90, p trend=0.03) and 0.33 (95% CI 0.14-0.80, p trend=0.07), respectively (Table 
6). No associations were detected in UC or for other dietary items in CD. When including only 
those who were diagnosed more than 3 years after recruitment (CD: n=85; UC: n=199), there 
was a significant inverse association of milk intake with UC (median time between recruitment 
and diagnosis 5.6 years) (adjusted OR for the highest versus lowest quartile 0.64, 95% CI 0.38-
1.07, p trend=0.04) and inverse but nonsignificant associations for other dietary items in UC or CD 
(Table 6).  
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Discussion 
In this large European prospective cohort study, no associations according to quartiles or trends 
between the intake of either total or specific dairy products (milk, yogurt, cheese) or dietary 
calcium and the development of incident CD or UC were demonstrated. However, individuals 
consuming milk were found to have significantly decreased odds of developing CD as compared 
to nonconsumers. Milk intake was inversely associated with colonic CD. Furthermore, there was 
an inverse association with total dairy products and milk intake in those diagnosed with CD less 
than five years following recruitment and with milk consumption in those diagnosed with UC 
more than three years after enrolment.  
Considering that ORs were less than one in most higher quartiles for both CD and UC, a 
protective threshold effect of dairy products and dietary calcium between the first and second 
quartile may exist. Accordingly, relatively low intakes of these dietary items might already have a 
beneficial effect, but the statistical power was insufficient to confirm this. The significant findings 
in CD cases diagnosed within five years of enrolment may suggest the influence of reverse 
causation. Information on the date of onset of symptoms attributed to IBD were not available. 
However, the median diagnostic delay for CD and UC is 5-9 months and 3-4 months, 
respectively.36-39 As individuals who developed IBD within 18 months after inclusion were 
excluded in this study, it seems unlikely that this affected our results importantly, although the 
possibility that individuals gave up milk products due to symptoms before diagnosis cannot be 
fully excluded. In those diagnosed more than three years following recruitment, nonsignificant 
but inverse associations were seen in CD and a significant inverse association between milk 
intake and UC was detected.   
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Evidence for a causal association are the plausible biological mechanisms, large effect sizes and 
temporality of the data collection. Several studies have reported that milk products potentially 
reduce intestinal inflammation, possibly by a direct modulation of inflammatory processes or by 
shaping of the gut microbiota.13-16 This may, for example, be related to vitamin D or result from 
an increased abundance of bacteria producing butyrate, an important colonic energy source, 
which is thought to interfere with the colitogenic environment.15,40,41 A recent experimental study 
in mice, however, demonstrated that consumption of milk-derived saturated fats results in the 
development of colitis through changes of the microbial community by altering the bile acid 
composition.17 This indicates that different dairy components, such as fats or proteins, may exert 
disparate effects, emphasizing that the exact mechanisms underlying these associations are still 
unclear. Overall, our findings suggest that milk consumption may have a predominantly 
protective effect in the etiology of CD, although an apparent dose-response relationship was 
not established.  
Previous epidemiological studies examining foods produced from milk and the development of 
CD or UC are sparse and show conflicting results. Some investigations report that a higher 
intake of milk is associated with a moderately increased risk of IBD,20,42 but other studies find an 
inverse association or none.21-25 These inconsistent findings could be explained by different 
study populations or by the different dietary items measured, such as milk proteins or 
unpasteurized milk, but might also have resulted from methodological limitations. Most 
investigations were retrospective case-control studies, which are prone to measurement bias for 
diet as these rely on patients recalling their diet before diagnosis, which may be many years 
previously.21-24 The only prospective investigation published to date could not detect a clear 
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association between IBD and dairy products (milk and cheese), but included only women and 
had a small sample size with 77 IBD cases.25  
The strength of our study was the prospective design, which minimizes recall and selection bias 
as dietary intakes were measured prior to diagnoses and both cases and controls were drawn 
from the same baseline population. Furthermore, the habitual diet of participants was assessed 
using validated FFQs that reflected local dietary habits. To ensure the validity of cases, all 
diagnoses were confirmed by gastroenterologists and participants with indeterminate or 
microscopic colitis were excluded. Follow-up bias is likely to be negligible, because the number 
of cases identified was similar to that expected.43 The odds of developing CD and UC were 
assessed separately with adjustments for covariates, such as smoking. Finally, the study 
population comprised both men and women from various European countries and the 
consumption of dairy products was in line with national surveys,44 thereby increasing the 
generalizability of our results. 
This study also had several limitations. FFQs may have a degree of misclassification and the 
assessment of the habitual diet of participants included just one measurement, which could 
have attenuated the effect sizes and possibly have masked small associations. Although 
participants may have altered their dietary habits during follow-up, previous studies 
demonstrated that general food patterns of adults remain relatively stable over time and we 
investigated categories (quartiles) of intake rather than specific amounts.45,46 Data on the intake 
of calcium supplements were not available, although in another investigation within EPIC regular 
use of such supplements was reported in less than 10% of German participants.47 Most patients 
in our study had late-onset disease, with IBD being diagnosed at an age of 50 years or older. 
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This may explain the relative predominance of colonic involvement in CD and limited disease 
extent in UC and might hamper the generalizability of these data to the whole IBD 
population.48,49 Furthermore, despite the relatively large sample size, our study might lack 
statistical power for subgroup analyses or to detect small effect sizes. Lastly, residual 
confounding, namely other etiological factors related to dairy products intake and the true 
causal exposure, could not be excluded in this observational study.  
In conclusion, although no clear dose-response relationship was observed, we found that 
individuals consuming milk have significantly reduced odds of developing CD as compared to 
nonconsumers with the effects occurring in those with colonic disease and diagnosed less than 
5 years after recruitment. Further studies are needed to confirm these findings and to identify 
any underlying mechanisms. 
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Table 1. Baseline characteristics of CD and UC cases and their controls 
 CD cases (n = 110) Controls (n = 440) UC cases (n = 244) Controls (n = 976) 
Female (n, %) 80 (72.7) 320 (72.7) 140 (57.4) 560 (57.4) 
Age (years) at recruitment (mean, SD) 50.1 (10.8) 50.1 (10.7) 51.7 (10.5) 51.7 (10.5) 
Age (years) at diagnosis (mean, SD) 55.4 (11.1) - 57.5 (10.3) - 
Distribution of CD (n, %) 
   L1, ileal 
   L2, colonic 
   L3, ileocolonic 
   L4, isolated upper GI disease 
   unknown 
 
31 (28.1) 
36 (32.7) 
28 (25.4) 
1 (1.0) 
14 (12.7) 
 
- 
- 
- 
- 
- 
 
- 
- 
- 
- 
- 
 
- 
- 
- 
- 
- 
Distribution of UC (n, %) 
   E1, ulcerative proctitis 
   E2, left sided colitis 
   E3, extensive colitis 
   extent not determined 
 
- 
- 
- 
- 
 
- 
- 
- 
- 
 
55 (22.5) 
86 (35.2) 
63 (25.8) 
40 (16.4) 
 
- 
- 
- 
- 
Smoking status (n, %) 
   never smoked 
   past smoker 
   current smoker 
   unknown 
 
41 (37.3) 
28 (25.5) 
38 (34.5) 
3 (2.7) 
 
209 (47.5) 
121 (27.5) 
107 (24.3) 
3 (0.7) 
 
65 (26.6) 
91 (37.3) 
82 (33.6) 
6 (2.5) 
 
418 (42.8) 
281 (28.8) 
255 (26.1) 
22 (2.3) 
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Table 1 (continued) 
 CD cases (n = 110) Controls (n = 440) UC cases (n = 244) Controls (n = 976) 
Total energy intake (kcal/day) (median, range) 2117.4 (789.6-4312.4) 2071.7 (900.1-4795.4) 2151.7 (906.8-4866.2) 2075.3 (697.4-5789.6) 
Total dairy products intake (g/day) (median, range) 280.9 (0.0-1131.4) 321.3 (18.6-1672.4) 290.6 (0.6-1729.4) 306.7 (6.4-2500.9) 
Milk intake (g/day) (median, range) 102.2 (0.0-914.6) 137.6 (0.0-1524.9) 129.5 (0.0-1482.5) 158.3 (0.0-2341.1) 
Yogurt intake (g/day) (median, range) 35.9 (0.0-480.0) 45.6 (0.0-455.1) 23.6 (0.0-452.6) 30.2 (0.0-615.3) 
Cheese intake (g/day) (median, range) 30.6 (0.0-160.5) 31.0 (0.0-248.2) 30.0 (0.0-245.4) 30.0 (0.0-678.2) 
Dietary calcium intake (mg/day) (median, range) 981.5 (273.1-4031.4) 959.1 (277.3-2852.9) 1000.8 (262.1-2572.1) 988.3 (214.5-4719.3) 
 
CD: Crohn’s disease; GI: gastrointestinal; UC: ulcerative colitis 
There were no significant differences in the dietary variables between CD or UC cases and controls. 
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Table 2. Odds of CD according to quartiles of dairy product and dietary calcium intake 
Dietary item Quartile of intake  
(ranges) 
Cases Controls Unadjusted OR  
(95% CI) 
Adjusted OR*  
(95% CI) 
Total dairy 
products (g/day) 
1 (0.0-176.9) 
2 (177.0-321.3) 
3 (321.4-515.4) 
4 (515.5-1672.4) 
 
36 
25 
23 
26 
109 
110 
110 
109 
1.00 
0.69 (0.38-1.21) 
0.61 (0.34-1.12) 
0.69 (0.38-1.26) 
p trend = 0.30 
1.00 
0.69 (0.38-1.24) 
0.55 (0.29-1.04) 
0.61 (0.32-1.19) 
p trend = 0.19 
Milk (g/day) 1 (0.0-21.4) 
2 (21.5-137.6) 
3 (137.7-296.0) 
4 (296.1-1524.9) 
 
38 
21 
23 
28 
109 
110 
110 
109 
 1.00 
0.53 (0.28-0.98) 
0.55 (0.29-1.05) 
0.69 (0.38-1.25) 
p trend = 0.55 
1.00 
0.53 (0.28-1.00) 
0.53 (0.28-1.03) 
0.61 (0.33-1.16) 
p trend = 0.36 
Yogurt (g/day) 1 (0.0-8.4) 
2 (8.5-45.6) 
3 (45.7-107.2) 
4 (107.3-480.0) 
 
31 
27 
30 
22 
109 
110 
110 
109 
1.00 
0.83 (0.44-1.56) 
0.92 (0.50-1.69) 
0.68 (0.36-1.30) 
p trend = 0.31 
1.00 
0.81 (0.42-1.56) 
0.97 (0.52-1.81) 
0.78 (0.40-1.52) 
p trend = 0.62 
Cheese (g/day) 1 (0.0-16.5) 
2 (16.6-31.0) 
3 (31.1-57.5) 
4 (57.6-248.2) 
 
28 
27 
29 
26 
109 
110 
110 
109 
1.00 
0.95 (0.52-1.73) 
1.03 (0.55-1.93) 
0.93 (0.48-1.80) 
p trend = 0.85 
1.00 
0.95 (0.52-1.76) 
0.95 (0.50-1.82) 
0.85 (0.42-1.72) 
p trend = 0.64 
Calcium (mg/day) 1 (273.1-730.4) 
2 (730.5-980.0) 
3 (980.1-1299.1) 
4 (1299.2-4031.4) 
 
25 
30 
33 
22 
109 
110 
110 
109 
1.00 
1.20 (0.66-2.17) 
1.31 (0.73-2.36) 
0.87 (0.46-1.65) 
p trend = 0.71 
1.00 
1.12 (0.61-2.08) 
0.97 (0.49-1.89) 
0.63 (0.28-1.42) 
p trend = 0.23 
 
CD: Crohn’s disease; CI: confidence interval; OR: odds ratio 
*adjusted for total energy intake and smoking status 
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Table 3. Odds of UC according to quartiles of dairy product and dietary calcium intake 
Dietary item Quartile of intake  
(ranges) 
Cases Controls Unadjusted OR  
(95% CI) 
Adjusted OR*  
(95% CI) 
Total dairy 
products (g/day) 
1 (0.0-174.6) 
2 (174.7-306.7) 
3 (306.8-477.3) 
4 (477.4-2500.9) 
64 
62 
61 
52 
243 
242 
243 
243 
1.00 
0.96 (0.64-1.44) 
0.94 (0.62-1.43) 
0.80 (0.51-1.24) 
p trend = 0.31 
1.00 
0.92 (0.60-1.40) 
0.95 (0.61-1.47) 
0.80 (0.50-1.30) 
p trend = 0.40 
Milk (g/day) 1 (0.0-28.3) 
2 (28.4-158.3) 
3 (158.4-294.6) 
4 (294.7-2341.1) 
 
71 
66 
46 
56 
243 
242 
248 
238 
 1.00 
0.94 (0.64-1.40) 
0.61 (0.40-0.95) 
0.78 (0.51-1.20) 
p trend = 0.22 
1.00 
0.93 (0.62-1.40) 
0.59 (0.37-0.93) 
0.81 (0.51-1.29) 
p trend = 0.32 
Yogurt (g/day) 1 (0.0-2.5) 
2 (2.6-30.2) 
3 (30.3-91.8) 
4 (91.9-615.3) 
 
63 
64 
55 
57 
243 
246 
240 
242 
1.00 
0.96 (0.63-1.47) 
0.85 (0.55-1.32) 
0.87 (0.57-1.35) 
p trend = 0.55 
1.00 
1.03 (0.67-1.59) 
0.88 (0.56-1.40) 
0.95 (0.60-1.48) 
p trend = 0.74 
Cheese (g/day) 1 (0.0-15.8) 
2 (15.9-30.0) 
3 (30.1-52.4) 
4 (52.5-678.2) 
 
66 
55 
59 
59 
242 
244 
242 
243 
1.00 
0.80 (0.54-1.19) 
0.86 (0.57-1.29) 
0.85 (0.54-1.31) 
p trend = 0.62 
1.00 
0.78 (0.52-1.18) 
0.84 (0.54-1.29) 
0.83 (0.52-1.32) 
p trend = 0.60 
Calcium (mg/day) 1 (214.5-751.5) 
2 (751.6-988.3) 
3 (988.4-1249.3) 
4 (1249.4-4719.3) 
 
67 
51 
66 
55 
243 
243 
243 
242 
1.00 
0.76 (0.51-1.16) 
0.99 (0.66-1.47) 
0.84 (0.56-1.26) 
p trend = 0.63 
1.00 
0.77 (0.50-1.19) 
1.00 (0.63-1.56) 
0.81 (0.49-1.34) 
p trend = 0.60 
 
CI: confidence interval; OR: odds ratio; UC: ulcerative colitis 
*adjusted for total energy intake and smoking status 
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Table 4. Odds of CD and UC according to milk consumption 
Dietary item Intake  Cases Controls Unadjusted OR 
(95% CI) 
Adjusted OR* 
(95% CI) 
CD 
 
Milk 
 
 
no consumption 
consumption 
 
 
20 
90 
 
 
44 
394 
 
 
1.00 
0.33 (0.15-0.72) 
 
 
1.00 
0.30 (0.13-0.65) 
UC 
 
Milk 
 
 
no consumption 
consumption 
 
 
27 
212 
 
 
86 
885 
 
 
1.00 
0.72 (0.43-1.23) 
 
 
1.00 
0.85 (0.49-1.47) 
 
CD: Crohn’s disease; CI: confidence interval; OR: odds ratio; UC: ulcerative colitis 
*adjusted for total energy intake and smoking status 
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Table 5. Odds of colonic and ileal CD according to quartiles of milk intake 
Dietary item Quartile of intake 
(ranges) 
Cases Controls Unadjusted OR  
(95% CI) 
Adjusted OR*  
(95% CI) 
Colonic CD 
 
Milk (g/day) 
 
 
1 (0.0-21.4) 
2 (21.5-137.6) 
3 (137.7-296.0) 
4 (296.1-1524.9) 
 
 
 
13 
6 
8 
9 
 
 
30 
21 
54 
38 
 
 
1.00 
0.68 (0.22-2.13) 
0.26 (0.09-0.80) 
0.43 (0.15-1.27) 
p trend = 0.22  
 
 
1.00 
0.57 (0.16-2.01) 
0.16 (0.04-0.59) 
0.23 (0.07-0.83) 
p trend = 0.07 
Ileal CD 
 
Milk (g/day) 
 
 
1 (0.0-21.4) 
2 (21.5-137.6) 
3 (137.7-296.0) 
4 (296.1-1524.9) 
 
 
 
13 
3 
7 
8 
 
 
40 
38 
18 
28 
 
 
 1.00 
0.24 (0.06-0.92) 
1.19 (0.39-3.59) 
0.93 (0.32-2.67) 
p trend = 0.62 
 
 
1.00 
0.23 (0.06-0.94) 
1.09 (0.34-3.47) 
0.89 (0.28-2.82) 
p trend = 0.66 
 
CD: Crohn’s disease; CI: confidence interval; OR: odds ratio 
*adjusted for total energy intake and smoking status 
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Table 6. Odds of CD in cases diagnosed more than 3 years or within 5 years after enrolment  
Dietary item Quartile of intake  
(ranges) 
Cases Controls Unadjusted OR  
(95% CI) 
Adjusted OR*  
(95% CI) 
CD cases diagnosed >3 years after inclusion 
 
Total dairy 
products (g/day) 
 
1 (0.0-176.9) 
2 (177.0-321.3) 
3 (321.4-515.4) 
4 (515.5-1672.4) 
 
 
27 
16 
21 
21 
 
87 
83 
86 
84 
 
1.00 
0.62 (0.31-1.24) 
0.77 (0.40-1.50) 
0.79 (0.40-1.56) 
p trend = 0.72 
 
1.00 
0.63 (0.31-1.28) 
0.68 (0.32-1.40) 
0.72 (0.34-1.53) 
p trend = 0.54 
Milk (g/day) 1 (0.0-21.4) 
2 (21.5-137.6) 
3 (137.7-296.0) 
4 (296.1-1524.9) 
 
26 
16 
21 
22 
88 
84 
87 
81 
 1.00 
0.63 (0.31-1.29) 
0.82 (0.41-1.66) 
0.92 (0.45-1.86) 
p trend = 0.84 
1.00 
0.65 (0.31-1.34) 
0.80 (0.38-1.67) 
0.84 (0.39-1.78) 
p trend = 0.95 
CD cases diagnosed <5 years after inclusion 
 
Total dairy 
products (g/day) 
 
1 (0.0-176.9) 
2 (177.0-321.3) 
3 (321.4-515.4) 
4 (515.5-1672.4) 
 
 
23 
12 
6 
12 
 
53 
49 
50 
58 
 
1.00 
0.55 (0.24-1.25) 
0.26 (0.10-0.70) 
0.44 (0.19-0.98) 
p trend = 0.05 
 
1.00 
0.55 (0.24-1.29) 
0.27 (0.10-0.76) 
0.36 (0.15-0.90) 
p trend = 0.03 
Milk (g/day) 1 (0.0-21.4) 
2 (21.5-137.6) 
3 (137.7-296.0) 
4 (296.1-1524.9) 
 
24 
8 
9 
12 
48 
52 
53 
57 
1.00 
0.27 (0.10-0.71) 
0.26 (0.10-0.69) 
0.38 (0.17-0.86) 
p trend = 0.10 
1.00 
0.28 (0.10-0.78) 
0.26 (0.09-0.71) 
0.33 (0.14-0.80) 
p trend = 0.07 
 
CD: Crohn’s disease; CI: confidence interval; OR: odds ratio 
*adjusted for total energy intake and smoking status 
